Best Stocks Under $2 Right Now It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. This page lists cheap stocks that have a share price of $2.00 (2 dollars) or less and consisently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts. OverviewStocks Under $0.05Stocks Under $0.10Stocks Under $0.25Stocks Under $0.50Stocks Under $1Stocks Under $2Stocks Under $3Stocks Under $5Stocks Under $10Stocks Under $20Stocks Under $30Stocks Under $50Stocks On Sale 1. Ur Energy NYSEAMERICAN:URG$1.60 +0.03 (+1.59%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur EnergyMarket Capitalization$633.74 millionConsensus RatingBuyConsensus Price Target$2.57 (+60.9% Upside)Volume4.05 million sharesAverage Volume9.41 million sharesToday's Range$1.55▼$1.62 Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. 2. iBio NASDAQ:IBIO$1.70 +0.04 (+2.10%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. More about iBioMarket Capitalization$84.70 millionConsensus RatingBuyConsensus Price Target$5.00 (+193.3% Upside)Volume304,885 sharesAverage Volume1.35 million sharesToday's Range$1.67▼$1.763. Inhibikase Therapeutics NASDAQ:IKT$1.68 +0.02 (+0.90%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. More about Inhibikase TherapeuticsMarket Capitalization$222.47 millionConsensus RatingBuyConsensus Price Target$5.40 (+220.5% Upside)Volume293,925 sharesAverage Volume1.37 million sharesToday's Range$1.67▼$1.724. Stereotaxis NYSEAMERICAN:STXS$1.82 +0.01 (+0.27%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. More about StereotaxisMarket Capitalization$178.38 millionConsensus RatingBuyConsensus Price Target$3.88 (+112.3% Upside)Volume112,276 sharesAverage Volume454,567 sharesToday's Range$1.81▼$1.865. Peraso NASDAQ:PRSO$0.95 -0.04 (-4.04%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Peraso Inc, a fabless semiconductor company, develops, markets, and sells semiconductor devices and modules. The company's products include millimeter wavelength (mmWave) ICs, including baseband IC, various mmWave radio frequency, integrated circuits, as well as associated antenna technology; and mmWave antenna modules. More about PerasoMarket Capitalization$14.02 millionConsensus RatingBuyConsensus Price Target$3.00 (+216.1% Upside)Volume451,262 sharesAverage Volume5.09 million sharesToday's Range$0.96▼$1.006. Autolus Therapeutics NASDAQ:AUTL$1.58 +0.03 (+1.60%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus TherapeuticsMarket Capitalization$421.86 millionConsensus RatingModerate BuyConsensus Price Target$8.75 (+452.1% Upside)Volume714,579 sharesAverage Volume1.72 million sharesToday's Range$1.52▼$1.647. Palisade Bio NASDAQ:PALI$1.74 -0.04 (-1.97%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. More about Palisade BioMarket Capitalization$302.90 millionConsensus RatingModerate BuyConsensus Price Target$10.20 (+484.5% Upside)Volume1.51 million sharesAverage Volume3.96 million sharesToday's Range$1.74▼$1.818. Context Therapeutics NASDAQ:CNTX$1.46 +0.05 (+3.17%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context TherapeuticsMarket Capitalization$134.60 millionConsensus RatingModerate BuyConsensus Price Target$6.60 (+350.5% Upside)Volume197,810 sharesAverage Volume1.23 million sharesToday's Range$1.43▼$1.519. Real Brokerage NASDAQ:REAX$1.62 +0.03 (+1.57%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.The Real Brokerage Inc, together with its subsidiaries, operates as a real estate technology company in the United States and Canada. More about Real BrokerageMarket Capitalization$346.30 millionConsensus RatingModerate BuyConsensus Price Target$5.69 (+252.2% Upside)Volume2.86 million sharesAverage Volume2.41 million sharesToday's Range$1.56▼$1.6710. Nouveau Monde Graphite NYSE:NMG$1.52 -0.01 (-0.33%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Nouveau Monde Graphite Inc engages in the acquisition, exploration, development, and evaluation of mineral properties in Quebec, Canada. More about Nouveau Monde GraphiteMarket Capitalization$243.66 millionConsensus RatingModerate BuyConsensus Price Target$4.67 (+208.0% Upside)Volume442,785 sharesAverage Volume1.09 million sharesToday's Range$1.48▼$1.5511. Tenaya Therapeutics NASDAQ:TNYA$0.71 -0.01 (-1.50%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya TherapeuticsMarket Capitalization$153.85 millionConsensus RatingModerate BuyConsensus Price Target$4.00 (+464.2% Upside)Volume866,806 sharesAverage Volume4.22 million sharesToday's Range$0.70▼$0.7312. MediciNova NASDAQ:MNOV$1.25 -0.03 (-2.34%) As of 01:47 PM Eastern This is a fair market value price provided by Massive. Learn more.MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. More about MediciNovaMarket Capitalization$61.53 millionConsensus RatingModerate BuyConsensus Price Target$7.50 (+500.0% Upside)Volume12,898 sharesAverage Volume52,268 sharesToday's Range$1.24▼$1.2613. Nano-X Imaging NASDAQ:NNOX$1.76 +0.05 (+2.63%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. More about Nano-X ImagingMarket Capitalization$122.20 millionConsensus RatingModerate BuyConsensus Price Target$5.00 (+184.9% Upside)Volume492,128 sharesAverage Volume1.27 million sharesToday's Range$1.71▼$1.8014. Metagenomi NASDAQ:MGX$1.25 0.00 (-0.24%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. More about MetagenomiMarket Capitalization$47.06 millionConsensus RatingModerate BuyConsensus Price Target$9.00 (+621.7% Upside)Volume31,463 sharesAverage Volume219,612 sharesToday's Range$1.24▼$1.2815. enCore Energy NASDAQ:EU$1.40 +0.03 (+2.19%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.enCore Energy Corp. engages in the acquisition, exploration, and development of uranium resource properties in the United States. More about enCore EnergyMarket Capitalization$272.92 millionConsensus RatingModerate BuyConsensus Price Target$3.83 (+173.8% Upside)Volume1.47 million sharesAverage Volume3.01 million sharesToday's Range$1.39▼$1.4716. DeFi Technologies NASDAQ:DEFT$0.54 0.00 (-0.19%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.DeFi Technologies, Inc engages in the provision of investment services. It plans to acquire equity, debt, or other securities of publicly traded or private companies or other entities. More about DeFi TechnologiesMarket Capitalization$210.32 millionP/E Ratio5.42Consensus RatingModerate BuyConsensus Price Target$2.00 (+271.1% Upside)Volume3.53 million sharesAverage Volume5.43 million shares17. NervGen Pharma NASDAQ:NGEN$1.89 +0.00 (+0.05%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. More about NervGen PharmaMarket Capitalization$152.80 millionConsensus RatingModerate BuyConsensus Price Target$18.00 (+851.9% Upside)Volume396,293 sharesAverage Volume420,223 sharesToday's Range$1.85▼$1.9418. Biomea Fusion NASDAQ:BMEA$1.20 +0.01 (+1.18%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More about Biomea FusionMarket Capitalization$86.40 millionConsensus RatingModerate BuyConsensus Price Target$8.50 (+606.0% Upside)Volume353,891 sharesAverage Volume1.35 million sharesToday's Range$1.17▼$1.2419. SelectQuote NYSE:SLQT$0.89 -0.03 (-3.11%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.SelectQuote, Inc operates a technology-enabled, direct-to-consumer distribution platform that sells a range of insurance products and healthcare services in the United States. More about SelectQuoteMarket Capitalization$156.95 millionP/E Ratio9.89Consensus RatingModerate BuyConsensus Price Target$3.00 (+237.8% Upside)Volume453,701 sharesAverage Volume1.67 million shares20. Humacyte NASDAQ:HUMA$1.08 -0.01 (-0.46%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. More about HumacyteMarket Capitalization$238.67 millionConsensus RatingModerate BuyConsensus Price Target$6.57 (+511.3% Upside)Volume5.69 million sharesAverage Volume6.78 million sharesToday's Range$1.05▼$1.1121. Black Diamond Therapeutics NASDAQ:BDTX$1.76 -0.06 (-3.02%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. More about Black Diamond TherapeuticsMarket Capitalization$101.13 millionConsensus RatingModerate BuyConsensus Price Target$10.00 (+466.6% Upside)Volume1.59 million sharesAverage Volume1.04 million sharesToday's Range$1.75▼$1.9222. InflaRx NASDAQ:IFRX$1.64 -0.04 (-2.08%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More about InflaRxMarket Capitalization$118.92 millionConsensus RatingModerate BuyConsensus Price Target$7.00 (+325.5% Upside)Volume480,203 sharesAverage Volume1.16 million sharesToday's Range$1.64▼$1.7423. Allogene Therapeutics NASDAQ:ALLO$1.90 +0.03 (+1.33%) As of 01:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. More about Allogene TherapeuticsMarket Capitalization$657.51 millionConsensus RatingModerate BuyConsensus Price Target$8.52 (+347.4% Upside)Volume5.40 million sharesAverage Volume8.19 million sharesToday's Range$1.86▼$1.9324. PepGen NASDAQ:PEPG$1.50 -0.02 (-0.99%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. More about PepGenMarket Capitalization$103.41 millionConsensus RatingModerate BuyConsensus Price Target$11.60 (+675.9% Upside)Volume137,680 sharesAverage Volume1.10 million sharesToday's Range$1.48▼$1.5525. ALX Oncology NASDAQ:ALXO$1.54 +0.03 (+1.64%) As of 01:52 PM Eastern This is a fair market value price provided by Massive. Learn more.ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. More about ALX OncologyMarket Capitalization$207.90 millionConsensus RatingModerate BuyConsensus Price Target$4.60 (+197.7% Upside)Volume321,207 sharesAverage Volume855,931 sharesToday's Range$1.49▼$1.60 More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
